ArticleNorthern clinics of Istanbul2025
Dual-phase images with 18F-FDG PET/CT can exhibit new lesions of colo-rectal cancer.
Article in Northern clinics of Istanbul, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDual-phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has demonstrated superiority over conventional imaging methods in various clinical conditions. However, its efficacy in detecting metastases from colorectal cancer is uncertain. We aim to reveal whether dual-phase FDG-PET/CT can be superior in detecting metastases compared to the standard PET-CT study in patients with an established diagnosis of colorectal cancer.
methodsThis is a single-center, retrospective case-control study involving 35 patients with colorectal cancer who underwent whole-body FDG PET-CT imaging. Late-phase FDG-PET-CT images were obtained 1-2 hours after the standard technique, emphasizing the identification of new lesions or clarified lesions.
resultsAmong the 35 patients evaluated, 5 (14.3%) exhibited new cancer lesions, while 6 (17.1%) demonstrated more evident cancer regions at late-phase FDG-PET-CT. New lesions or more evident cancer regions with the dual-phase technique were described within the liver, in regional lymph nodes, and in peritumoral regions.
conclusionThe study findings suggest that dual-phase FDG-PET-CT can reveal new and more evident metastatic lesions in a subset of colorectal cancer patients. This technique, precious in identifying liver metastases and lymph nodes, enhances the accuracy of colorectal cancer diagnosis and staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.